Efficacy and Safety of Eliapixant in Overactive Bladder: The 12-Week, Randomised, Placebo-controlled Phase 2a OVADER Study

被引:3
作者
Ewerton, Flavio [1 ]
Cruz, Francisco [2 ,3 ,4 ]
Kapp, Moritz [1 ]
Klein, Stefan [1 ]
Roehm, Petra [5 ]
Chapple, Christopher [6 ]
机构
[1] Bayer AG, Mullerstr 178, D-13353 Berlin, Germany
[2] Sao Joao Univ Hosp Ctr, Dept Urol, Porto, Portugal
[3] Univ Porto, Fac Med, Porto, Portugal
[4] Univ Porto, I3S Inst Invest & Innovat Hlth, Porto, Portugal
[5] Bayer AG, Leverkusen, Germany
[6] Sheffield Teaching Hosp NHS Fdn Trust, Royal Hallamshire Hosp, Dept Urol, Sheffield, England
来源
EUROPEAN UROLOGY FOCUS | 2024年 / 10卷 / 01期
关键词
Overactive bladder; Urgency urinary incontinence; Eliapixant; MICE REVEAL; MIRABEGRON; INCONTINENCE; RECEPTORS; SYMPTOMS; P2X(3); WOMEN; P2X3;
D O I
10.1016/j.euf.2023.07.008
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Effective, well -tolerated novel treatments for overactive bladder (OAB) are lacking. The P2X3 receptor antagonist eliapixant demonstrated potential to reduce OAB symptoms in preclinical studies. Objective: To evaluate the safety, tolerability, and efficacy of eliapixant in patients with OAB with urgency urinary incontinence (UUI). Design, setting and participants: OVADER was a 12 -wk, randomised, placebo -controlled, double-blind, parallel -group, multicentre, phase 2a study (NCT04545580) conducted between 2020 and 2022 in private and institutional clinical practices. Eligible patients were aged >= 18 yr with wet OAB symptoms (urgency, urinary frequency, and urinary incontinence) for >= 3 mo before screening. Intervention: Randomisation (1:1 ratio) to oral eliapixant 125 mg or placebo twice daily. Outcome measurements and statistical analysis: The primary endpoint was the mean change from baseline in the mean number of UUI episodes/24 h over weeks 4, 8, and 12 according to an electronic bladder diary, evaluated using a repeated -measurement model in a Bayesian framework. Results and limitations: Of 202 patients enrolled, 85 were valid for per -protocol analysis. The primary efficacy endpoint was not met. The posterior probability for eliapixant superiority over placebo was 40% (point estimate 0.05, 95% credible interval -00 to 0.38), which did not meet the predefined criterion of >= 90% probability. Secondary and exploratory endpoints were not met. The incidence of adverse events was similar in the eliapixant (n = 32, 63%) and placebo (n = 27, 56%) groups; most were mild and five led to discontinuation of eliapixant. Conclusions: OVADER did not meet its clinical efficacy endpoints. Potential reasons include the nonspecific OAB symptom complex, the poorly understood pathophysiology, and the coinciding COVID-19 pandemic.
引用
收藏
页码:90 / 97
页数:8
相关论文
共 30 条
  • [1] Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care
    Ali, Mahmood
    Grogan, Sarah
    Powell, Sue
    Staniford, Leanne
    Nazir, Jameel
    Landeira, Margarita
    Covernton, Patrick J. O.
    Jaggi, Ashley
    Fatoye, Francis
    Holt, Maxine
    [J]. ADVANCES IN THERAPY, 2019, 36 (11) : 3110 - 3122
  • [2] [Anonymous], 2009, Drug-Induced Liver Injury: Premarketing Clinical Evaluation - Guidance for Industry [Internet]
  • [3] Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity
    Apostolidis, A
    Popat, R
    Yiangou, Y
    Cockayne, D
    Ford, APDW
    Davis, JB
    Dasgupta, P
    Fowler, CJ
    Anand, P
    [J]. JOURNAL OF UROLOGY, 2005, 174 (03) : 977 - 982
  • [4] Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem
    Banakhar, Mai Ahmed
    Al-Shaiji, Tariq
    Hassouna, Magdy
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2012, 4 (04) : 179 - 185
  • [5] Purinergic Signalling: Therapeutic Developments
    Burnstock, Geoffrey
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [6] Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year
    Chapple, Christopher R.
    Kaplan, Steven A.
    Mitcheson, David
    Blauwet, Mary Beth
    Huang, Moses
    Siddiqui, Emad
    Khullar, Vik
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (10) : 960 - 967
  • [7] A Proof-of-Concept Study: Mirabegron, a New Therapy for Overactive Bladder
    Chapple, Christopher R.
    Amarenco, Gerard
    Lopez Aramburu, Miguel A.
    Everaert, Karel
    Liehne, Josef
    Lucas, Malcolm
    Vik, Viktor
    Ridder, Arwin
    Snijder, Robert
    Yamaguchi, Osamu
    [J]. NEUROUROLOGY AND URODYNAMICS, 2013, 32 (08) : 1116 - 1122
  • [8] P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP
    Cockayne, DA
    Dunn, PM
    Zhong, Y
    Rong, WF
    Hamilton, SG
    Knight, GE
    Ruan, HZ
    Ma, B
    Yip, P
    Nunn, P
    McMahon, SB
    Burnstock, G
    Ford, APDW
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 2005, 567 (02): : 621 - 639
  • [9] The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study
    Coyne, Karin S.
    Sexton, Chris C.
    Irwin, Debra E.
    Kopp, Zoe S.
    Kelleher, Con J.
    Milsom, Ian
    [J]. BJU INTERNATIONAL, 2008, 101 (11) : 1388 - 1395
  • [10] Economic Burden of Urgency Urinary Incontinence in the United States: A Systematic Review
    Coyne, Karin S.
    Wein, Alan
    Nicholson, Sean
    Kvasz, Marion
    Chen, Chieh-I
    Milsom, Ian
    [J]. JOURNAL OF MANAGED CARE PHARMACY, 2014, 20 (02): : 130 - 140